Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model. - Archive ouverte HAL Access content directly
Journal Articles Experimental Parasitology Year : 2012

Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model.

(1) , (1) , (1) , (1) , (1, 2) , (1) , (1) , (3) , (1)
1
2
3

Abstract

An intercellular spreading strategy using herpes simplex virus type 1 (HSV-1) VP22 protein is employed to enhance DNA vaccine potency of Leishmania major amastin antigen in BALB/c mice model. We evaluated the immunogenicity and protective efficacy of plasmid DNA vaccines encoding amastin-enhanced green fluorescent protein (EGFP) and VP22-amastin-EGFP. Optimal cell-mediated immune responses were observed in BALB/c mice immunized with VP22-amastin-EGFP as assessed by cytokine gene expression analysis using real time RT-PCR. Vaccination with the VP22-amastin-EGFP fusion construct elicited significantly higher IFN-gamma response upon antigen stimulation of splenocytes from immunized mice compared to amastin as a sole antigen. Mice immunized by VP22-amastin-EGFP showed partial protection following infectious challenge with L. major, as measured by parasite load in spleens. These results suggest that the development of DNA vaccines encoding VP22 fused to a target Leishmania antigen would be a promising strategy to improve immunogenicity and DNA vaccine potency.
Not file

Dates and versions

pasteur-00786634 , version 1 (09-02-2013)

Identifiers

Cite

Azam Bolhassani, Elham Gholami, Farnaz Zahedifard, Neda Moradin, Parto Parsi, et al.. Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model.. Experimental Parasitology, 2012, 128 (1), pp.9-17. ⟨10.1016/j.exppara.2011.01.012⟩. ⟨pasteur-00786634⟩

Collections

RIIP RIIP_IRAN
36 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More